Abstract
SOCS2 is a pleiotropic E3 ligase. Its deficiency is associated with gigantism and organismal lethality upon inflammatory challenge. However, mechanistic understanding of SOCS2 function is dismal due to our unawareness of its protein substrates. We performed a mass spectrometry based proteomic profiling upon SOCS2 depletion and yield quantitative data for ~4200 proteins. Through this screen we identify a novel target of SOCS2, the serine-threonine kinase NDR1. Over-expression of SOCS2 accelerates turnover, while its knockdown stabilizes, endogenous NDR1 protein. SOCS2 interacts with NDR1 and promotes its degradation through K48-linked ubiquitination. Functionally, over-expression of SOCS2 antagonizes NDR1-induced TNFα-stimulated NF-κB activity. Conversely, depletion of NDR1 rescues the effect of SOCS2-deficiency on TNFα-induced NF-κB transactivation. Using a SOCS2−/− mice model of colitis we show that SOCS2-deficiency is pro-inflammatory and negatively correlates with NDR1 and nuclear p65 levels. Lastly, we provide evidence to suggest that NDR1 acts as an oncogene in prostate cancer. To the best of our knowledge, this is the first report of an identified E3 ligase for NDR1. These results might explain how SOCS2-deficiency leads to hyper-activation of NF-κB and downstream pathological implications and posits that SOCS2 induced degradation of NDR1 may act as a switch in restricting TNFα-NF-κB pathway.
The suppressor of cytokine signaling 2 (SOCS2) is one of the substrate recognition modules of Cullin5/Rbx2 ubiquitin ligases. Classically, SOCS2 has been well-studied for its regulatory role on growth hormone (GH) signaling1,2. However, subsequent studies have found that this E3 ligase is an important regulator of inflammation. SOCS2 function is vital for maintaining immune homeostasis and its defects have been implicated in sepsis related mortality in mice models due to an exacerbated inflammatory response3,4. NF-κB signaling is centrally important to inflammatory processes5 and consequently, functional interactions between SOCS2 and NF-κB signaling have been studied6,7. We have previously described an inhibitory role of SOCS2 on NF-κB activation in macrophages and a recent study describe a similar finding in brain astrocytes8,9.
At the molecular level our understanding of SOCS2 function is limited. This is, in part, due to the pleiotropic nature of SOCS210,11,12; but mostly due to our unawareness about its physiological protein substrates. Apart from GH receptor, substrates identified for SOCS2 till date, with relevance to inflammation, includes SOCS313 and p-Pyk214. SOCS2 destabilized SOCS3 and enhanced STAT signaling in response to IL-2/3 in T cells. Similarly, SOCS2 augmented IL-15 induced NK cell priming by degrading phospho-(Y402)-Pyk2. The status of NF-κB signaling were not evaluated in these studies. Clearly, the mechanisms of action of SOCS2 with respect to NF-κB signaling needs further exploration.
In order to identify and characterize bona-fide targets of SOCS2 we utilized mass spectrometry to quantify protein levels for thousands of proteins in cells depleted of SOCS2. This investigation lead to the identification of a number of proteins that could mediate the interplay between SOCS2 and NF-κB. In this investigation, the relationship between SOCS2 and NDR1 and its consequence for NF-κB activation is explored in detail.
Results
Quantitative proteomic screen of SOCS2 depleted cells identifies novel putative targets
We began our study by performing an unbiased proteomic screen to identify potential substrates of SOCS2. Physiological substrates of SOCS2 that are degraded in its presence are expected to accumulate when SOCS2 is depleted. We used an RNAi knock-down approach to avoid secondary effects of long-term SOCS2 depletion. Expression of SOCS2 was quantitated using immunoblotting (IB) (Fig. 1A). The overall effect on cell proliferation was measured by FACS (Fig. 1B), showing minor effects in the cell cycle upon SOCS2 depletion in mouse embryonic fibroblasts (MEFs). We characterized the proteome of SOCS2 wild-type (SOCS2WT) and knock-down (SOCS2KD) MEFs using nanoLC-MS/MS (nanoscale liquid chromatography coupled to tandem mass spectrometry) based proteomics (Fig. 1C). Three independent experiments were carried out using two different siRNAs against SOCS2, resulting in biological triplicates of essentially two biological groups. MS data of the biological triplicates from both groups were combined and analyzed by using a combination of MaxQuant and Perseus (see Methods). Relative label-free quantification (LFQ) was fairly reproducible between the triplicates, while some variation was observed across the different groups as depicted by principle component analysis (Fig. 1D). Overall, using this approach we detected ~5000 proteins and document quantitative data for >4200 proteins upon SOCS2 depletion (Fig. 1E). Expression of most proteins (94.6%) were unaltered and only a very small subset of proteins (5.4%), which satisfied the criteria of a fold-change (±) of ≥1.5 and P-value < 0.05, showed differences between SOCS2WT and SOCS2KD MEFs (Table 1 and Table S1). No expression of SOCS2 or its previously identified target, the GHR (growth hormone receptor), was detected most likely due to their low abundances15.
Table 1. Upregulated proteins identified in the proteomics screen which satisfied the criteria of a fold-change of >1.5 and P-value < 0.05.
Majority protein IDs | Protein names | Gene names | P value (−Log10) | Difference (Log2) | Unique peptides | Mol. weight [kDa] |
---|---|---|---|---|---|---|
Q8K298 | Actin-binding protein anillin | Anln | 5.145 | 2.026 | 18 | 122.79 |
Q9CYW4 | Haloacid dehalogenase-like hydrolase domain-containing protein 3 | Hdhd3 | 1.899 | 1.633 | 4 | 28.027 |
Q3TFD2 | Lysophosphatidylcholine acyltransferase 1 | Lpcat1 | 2.301 | 1.605 | 3 | 54.649 |
Q78XF5 | Oligosaccharyltransferase complex subunit OSTC | Ostc | 3.778 | 1.604 | 2 | 16.815 |
Q9D3D9 | ATP synthase subunit delta, mitochondrial | Atp5d | 2.552 | 1.560 | 5 | 17.6 |
Q9CR41 | Huntingtin-interacting protein K | Hypk | 2.786 | 1.560 | 4 | 14.679 |
Q05CN2 | Ribosomal RNA processing protein 1 homolog A | Rrp1 | 1.762 | 1.529 | 4 | 42.904 |
Q9CXG3 | Peptidyl-prolyl cis-trans isomerase-like 4 | Ppil4 | 2.440 | 1.485 | 10 | 57.23 |
Q0KL02 | Triple functional domain protein | Trio | 2.018 | 1.398 | 7 | 288.71 |
Q80ZX0 | Protein Sec24b | Sec24b | 2.144 | 1.358 | 9 | 135.55 |
Q5XF89 | Probable cation-transporting ATPase 13A3 | Atp13a3 | 2.296 | 1.339 | 3 | 137.47 |
Q9CR27 | WASH complex subunit CCDC53 | Ccdc53 | 2.265 | 1.323 | 3 | 21.092 |
F2Z4B3 | Cyclin-dependent kinase 2-associated protein 1 | Cdk2ap1 | 2.562 | 1.258 | 3 | 9.6308 |
Q4KML4 | Costars family protein ABRACL | Abracl | 4.853 | 1.254 | 5 | 9.0303 |
P16254 | Signal recognition particle 14 kDa protein | Srp14 | 3.115 | 1.250 | 6 | 12.51 |
Q8CHT1 | Ephexin-1 | Ngef | 4.329 | 1.243 | 6 | 71.415 |
Q99LC8 | Translation initiation factor eIF-2B subunit alpha | Eif2b1 | 1.667 | 1.217 | 7 | 33.816 |
Q3TME9 | Tyrosine-protein kinase Fer | Fer | 3.260 | 1.209 | 4 | 45.071 |
Q6ZQK0 | Condensin-2 complex subunit D3 | Ncapd3 | 3.285 | 1.189 | 12 | 169.43 |
Q8BW84 | Glutamyl-tRNA(Gln) amidotransferase subunit B, mitochondrial | Pet112 | 3.543 | 1.180 | 5 | 61.509 |
E9Q555 | E3 ubiquitin-protein ligase RNF213 | Rnf213 | 2.675 | 1.138 | 18 | 584.49 |
Q8R5C5 | Beta-centractin | Actr1b | 1.997 | 1.098 | 6 | 42.281 |
Q9DCJ5 | NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 8 | Ndufa8 | 3.935 | 1.098 | 5 | 19.992 |
Q8BGB7 | Enolase-phosphatase E1 | Enoph1 | 2.729 | 1.096 | 3 | 25.358 |
Q52L97 | Importin subunit alpha | Kpna2 | 4.766 | 1.053 | 14 | 57.927 |
P62077 | Mitochondrial import inner membrane translocase subunit Tim8 B | Timm8b | 4.695 | 1.034 | 3 | 9.2864 |
Q99LT0 | Protein dpy-30 homolog | Dpy30 | 3.094 | 1.015 | 4 | 11.213 |
E9PY48 | Condensin-2 complex subunit H2 | Ncaph2 | 1.970 | 1.010 | 4 | 65.309 |
Q9EPL8 | Importin-7 | Ipo7 | 4.506 | 0.978 | 20 | 119.49 |
Q9DAS3 | Dynein light chain Tctex-type 1 | Dynlt1f | 3.252 | 0.960 | 3 | 11.625 |
Q91WK1 | SPRY domain-containing protein 4 | Spryd4 | 2.463 | 0.937 | 7 | 23.275 |
Q6P4T3 | Eyes absent homolog 3 | Eya3 | 2.519 | 0.924 | 13 | 57.854 |
Q9D1R2 | Protein KTI12 homolog | Kti12 | 1.877 | 0.905 | 4 | 38.444 |
D5MCW4 | Protein CutA | Cuta | 3.344 | 0.897 | 3 | 16.453 |
Q543N6 | Serine/threonine-protein phosphatase 2 A activator | Ppp2r4 | 2.280 | 0.897 | 15 | 36.71 |
Q9CRT8 | Exportin-T | Xpot | 2.742 | 0.888 | 15 | 109.73 |
A2AEB4 | Mortality factor 4-like protein 2 | Morf4l2 | 2.734 | 0.886 | 6 | 22.919 |
Q9CQK7 | RWD domain-containing protein 1 | Rwdd1 | 2.170 | 0.884 | 6 | 27.785 |
D3YYC2 | Dr1-associated corepressor | Drap1 | 3.189 | 0.863 | 4 | 17.587 |
Q8CC06 | Integrin alpha-6 | Itga6 | 2.066 | 0.859 | 12 | 119.6 |
Q3UB06 | SRSF protein kinase 1 | Srpk1 | 4.142 | 0.856 | 10 | 73.088 |
Q9D7A8 | Armadillo repeat-containing protein 1 | Armc1 | 2.063 | 0.851 | 4 | 31.246 |
Q9CZ30 | Obg-like ATPase 1 | Ola1 | 3.529 | 0.846 | 21 | 44.729 |
P08030 | Adenine phosphoribosyltransferase | Aprt | 3.618 | 0.844 | 12 | 19.724 |
Q5SSZ5 | Tensin-3 | Tns3 | 3.978 | 0.840 | 1 | 58.725 |
Q3UTL4 | High affinity cationic amino acid transporter 1 | Slc7a1 | 2.364 | 0.835 | 3 | 67.107 |
Q8VDF2 | E3 ubiquitin-protein ligase UHRF1 | Uhrf1 | 3.938 | 0.829 | 20 | 87.555 |
Q9CPY1 | 39 S ribosomal protein L51, mitochondrial | Mrpl51 | 3.421 | 0.822 | 4 | 15.103 |
Q6PE15 | Mycophenolic acid acyl-glucuronide esterase, mitochondrial | Abhd10 | 2.757 | 0.821 | 6 | 33.04 |
Q548K2 | Alcohol dehydrogenase class 4 mu/sigma chain | Adh7 | 2.849 | 0.819 | 9 | 39.837 |
Q9CY16 | 28 S ribosomal protein S28, mitochondrial | Mrps28 | 3.494 | 0.817 | 7 | 20.52 |
G3XA18 | N-acylethanolamine-hydrolyzing acid amidase | Naaa | 1.903 | 0.807 | 3 | 39.803 |
Q8R5H1 | Ubiquitin carboxyl-terminal hydrolase 15 | Usp15 | 4.365 | 0.803 | 28 | 112.32 |
Q3UMQ8 | H/ACA ribonucleoprotein complex non-core subunit NAF1 | Naf1 | 2.307 | 0.802 | 3 | 53.245 |
O70591 | Prefoldin subunit 2 | Pfdn2 | 4.651 | 0.798 | 7 | 16.534 |
Q8C845 | EF-hand domain-containing protein D2 | Efhd2 | 1.873 | 0.795 | 7 | 26.8 |
Q6P9R1 | ATP-dependent RNA helicase DDX51 | Ddx51 | 3.675 | 0.791 | 14 | 70.367 |
E9PUB0 | Arf-GAP with Rho-GAP domain, ANK repeat and PH domain-containing protein 1 | Arap1 | 2.705 | 0.780 | 8 | 83.2 |
Q7TMR0 | Lysosomal Pro-X carboxypeptidase | Prcp | 5.910 | 0.777 | 13 | 55.026 |
Q9JJ44 | DUTPase | Dut | 3.584 | 0.777 | 7 | 17.414 |
Q921M8 | Ubiquitin carboxyl-terminal hydrolase | Usp4 | 1.494 | 0.769 | 20 | 103.75 |
E9PX53 | Serine/threonine-protein phosphatase 4 regulatory subunit 1 | Ppp4r1 | 1.509 | 0.765 | 8 | 104.5 |
Q9D046 | Centrin-3 | Cetn3 | 2.665 | 0.762 | 3 | 19.447 |
Q99LZ3 | DNA replication complex GINS protein SLD5 | Gins4 | 1.888 | 0.760 | 4 | 25.961 |
Q9JKB3 | Y-box-binding protein 3 | Ybx3 | 3.254 | 0.757 | 1 | 38.813 |
Q6PDL0 | Cytoplasmic dynein 1 light intermediate chain 2 | Dync1li2 | 2.409 | 0.754 | 9 | 54.218 |
Q80 × 98 | DEAH (Asp-Glu-Ala-His) box polypeptide 38 | Dhx38 | 2.570 | 0.754 | 19 | 140.62 |
Q561N4 | Ubiquitin-conjugating enzyme E2 L3 | Ube2l3 | 1.881 | 0.746 | 1 | 17.861 |
Q8C6I2 | Succinate dehydrogenase assembly factor 2, mitochondrial | Sdhaf2 | 3.361 | 0.745 | 6 | 19.431 |
Q8K2A7 | Integrator complex subunit 10 | Ints10 | 2.772 | 0.739 | 10 | 82.019 |
Q8K4L0 | ATP-dependent RNA helicase DDX54 | Ddx54 | 1.902 | 0.739 | 13 | 97.747 |
Q5SW19 | Clustered mitochondria protein homolog | Cluh | 3.374 | 0.736 | 13 | 148.07 |
Q6A009 | E3 ubiquitin-protein ligase listerin | Ltn1 | 2.232 | 0.729 | 10 | 198.92 |
Q545F0 | Macrophage migration inhibitory factor | Mif | 3.086 | 0.728 | 9 | 12.504 |
Q9DBY0 | Forkhead box protein P4 | Foxp4 | 3.890 | 0.722 | 7 | 72.758 |
Q8R404 | Protein QIL1 | Qil1 | 2.812 | 0.722 | 6 | 13.373 |
Q86Y56 | Dynein assembly factor 5, axonemal | Heatr2 | 1.698 | 0.722 | 6 | 93.85 |
Q3TBW2 | 39 S ribosomal protein L10, mitochondrial | Mrpl10 | 2.758 | 0.719 | 5 | 29.395 |
E9PWB1 | Pleckstrin homology-like domain family B member 1 | Phldb1 | 3.099 | 0.716 | 32 | 145.04 |
P70698 | CTP synthase 1 | Ctps1 | 3.766 | 0.715 | 29 | 66.682 |
Q3UMC0 | Spermatogenesis-associated protein 5 | Spata5 | 1.550 | 0.710 | 5 | 97.255 |
Q922Y1 | UBX domain-containing protein 1 | Ubxn1 | 3.403 | 0.709 | 8 | 33.572 |
Q8K4F6 | Putative methyltransferase NSUN5 | Nsun5 | 2.148 | 0.708 | 6 | 51.029 |
Q64261 | Cyclin-dependent kinase 6 | Cdk6 | 6.123 | 0.706 | 5 | 37.028 |
J3QP71 | Basigin | Bsg | 2.028 | 0.703 | 7 | 21.602 |
Q99M31 | Heat shock 70 kDa protein 14 | Hspa14 | 3.418 | 0.701 | 13 | 54.65 |
Q63870 | Collagen alpha-1(VII) chain | Col7a1 | 3.142 | 0.699 | 13 | 295.23 |
A2A6Q5 | Cell division cycle protein 27 homolog | Cdc27 | 2.122 | 0.696 | 6 | 91.841 |
Q9CRA5 | Golgi phosphoprotein 3 | Golph3 | 1.933 | 0.691 | 9 | 33.752 |
Q9JIK5 | Nucleolar RNA helicase 2 | Ddx21 | 5.098 | 0.690 | 59 | 93.55 |
Q6ZPJ3 | Ubiquitin-conjugating enzyme E2 O | Ube2o | 2.910 | 0.689 | 7 | 140.83 |
Q3UVH2 | Tyrosine-protein kinase CSK | Csk | 2.833 | 0.687 | 12 | 50.73 |
Q63829 | COMM domain-containing protein 3 | Commd3 | 2.101 | 0.680 | 5 | 22.037 |
Q9R0H0 | Peroxisomal acyl-coenzyme A oxidase 1 | Acox1 | 2.545 | 0.675 | 14 | 74.717 |
Q3UA06 | Pachytene checkpoint protein 2 homolog | Trip13 | 1.747 | 0.670 | 8 | 48.376 |
Q8R3P6 | von Willebrand factor A domain-containing protein 9 | Vwa9 | 2.231 | 0.670 | 7 | 57.236 |
Q921Q7 | Ras and Rab interactor 1 | Rin1 | 1.329 | 0.664 | 4 | 83.013 |
P62488 | DNA-directed RNA polymerase II subunit RPB7 | Polr2g | 2.233 | 0.663 | 7 | 19.294 |
Q6NS79 | Protein diaphanous homolog 1 | Diap1 | 2.186 | 0.662 | 16 | 135.84 |
Q8BL74 | General transcription factor 3 C polypeptide 2 | Gtf3c2 | 2.088 | 0.659 | 6 | 100.27 |
J3QMC5 | Midasin | Mdn1 | 2.800 | 0.659 | 41 | 629.58 |
Q91VJ4 | Serine/threonine-protein kinase 38 | Stk38 | 1.602 | 0.659 | 4 | 54.174 |
Q8R126 | Gltscr2 protein | Gltscr2 | 2.771 | 0.658 | 7 | 54.506 |
Q3U8P5 | Vacuolar protein sorting-associated protein 4B | Vps4b | 3.743 | 0.656 | 8 | 49.464 |
F8VQ54 | Endoribonuclease Dicer | Dicer1 | 1.684 | 0.655 | 7 | 215.77 |
P70444 | BH3-interacting domain death agonist | Bid | 1.761 | 0.650 | 5 | 21.951 |
Q8C079 | Striatin-interacting protein 1 | Strip1 | 1.444 | 0.648 | 7 | 86.884 |
Q9EQ80 | NIF3-like protein 1 | Nif3l1 | 2.376 | 0.644 | 10 | 41.745 |
E9QAP7 | Protein Taf | Taf4a | 1.489 | 0.643 | 5 | 73.137 |
Q3THE6 | Ferritin | Ftl1 | 3.246 | 0.628 | 2 | 20.695 |
Q3UUQ7 | GPI inositol-deacylase | Pgap1 | 2.451 | 0.628 | 2 | 104.58 |
Q3THG5 | Cyclin-dependent kinase 7 | Cdk7 | 1.353 | 0.626 | 4 | 38.968 |
Q9D071 | MMS19 nucleotide excision repair protein homolog | Mms19 | 1.478 | 0.626 | 8 | 97.458 |
Q9QY06 | Unconventional myosin-IXb | Myo9b | 3.626 | 0.620 | 11 | 238.83 |
A3KMJ8 | Prefoldin subunit 3 | Vbp1 | 3.410 | 0.619 | 9 | 21.963 |
Q6ZQH8 | Nucleoporin NUP188 homolog | Nup188 | 2.879 | 0.618 | 21 | 196.69 |
Q9DC50 | Peroxisomal carnitine O-octanoyltransferase | Crot | 1.812 | 0.617 | 6 | 70.264 |
Q5PPR2 | Exocyst complex component 1 | Exoc1 | 1.615 | 0.616 | 5 | 100.19 |
Q9CZD3 | Glycine–tRNA ligase | Gars | 3.168 | 0.609 | 38 | 81.877 |
Q9CSZ1 | BTB/POZ domain-containing protein KCTD5 | Kctd5 | 1.377 | 0.606 | 2 | 18.877 |
Q8BVG4 | Dipeptidyl peptidase 9 | Dpp9 | 2.135 | 0.603 | 10 | 98 |
A6H5Z3 | Exocyst complex component 6B | Exoc6b | 1.806 | 0.601 | 5 | 94.128 |
F8VQJ3 | Laminin subunit gamma-1 | Lamc1 | 3.495 | 0.601 | 24 | 177.19 |
Q9D358 | Low molecular weight phosphotyrosine protein phosphatase | Acp1 | 1.924 | 0.600 | 7 | 18.192 |
Q80VI1 | E3 ubiquitin-protein ligase TRIM56 | Trim56 | 2.562 | 0.598 | 10 | 79.512 |
Q3UHB1 | 5-nucleotidase domain-containing protein 3 | Nt5dc3 | 2.245 | 0.598 | 11 | 63.17 |
P11440 | Cyclin-dependent kinase 1 | Cdk1 | 3.618 | 0.598 | 14 | 34.106 |
Q9JJY4 | Probable ATP-dependent RNA helicase DDX20 | Ddx20 | 1.349 | 0.597 | 8 | 91.709 |
Q99K58 | Fibulin-2 | Fbln2 | 1.933 | 0.596 | 6 | 126.46 |
Q8WTY4 | Anamorsin | Ciapin1 | 2.119 | 0.596 | 9 | 33.429 |
Q8BJ03 | Cytochrome c oxidase assembly protein COX15 homolog | Cox15 | 1.314 | 0.595 | 3 | 44.005 |
Q3TKX4 | Probable ATP-dependent RNA helicase DDX52 | Ddx52 | 2.903 | 0.595 | 20 | 67.129 |
Q9DB96 | Neuroguidin | Ngdn | 2.196 | 0.594 | 5 | 35.658 |
Q5SWU9 | Acetyl-CoA carboxylase 1 | Acaca | 3.318 | 0.593 | 26 | 265.25 |
P46664 | Adenylosuccinate synthetase isozyme 2 | Adss | 3.358 | 0.591 | 25 | 50.02 |
Q6WKZ8 | E3 ubiquitin-protein ligase UBR2 | Ubr2 | 2.034 | 0.586 | 18 | 199.2 |
Both endogenous and exogenously expressed NDR1 is destabilized by SOCS2
Bioinformatics analysis and text mining of significantly upregulated proteins in our dataset identified a handful of proteins previously associated with the regulation of NF-κB activity (See Fig. 1E). Literature review indicated that FER, GOLPH3 and STK38 upregulates NF-κB activity16,17,18. Given the recently published link between NDR1(STK38) and TNFα-induced NF-κB activation, we focussed our attention on NDR1. To investigate the possibility that SOCS2 regulates NDR1, we first used immunoblotting (IB) to verify that depletion of SOCS2 by siRNAs indeed increased the cellular levels of endogenous NDR1 protein under resting conditions (Fig. 2A) and when de novo protein synthesis has been blocked using cycloheximide (Fig. 2B). Over-expressed FLAGSOCS2 could decrease endogenous NDR1 protein but not mRNA (Fig. 2C–E). Furthermore, FLAGSOCS2 could destabilize exogenously expressed MycNDR1 in MEFs in a dose-dependent manner (Fig. 2F) and in a panel of different cell lines (Fig. 2G). We also observed that FLAGSOCS2WT but not FLAGSOCS2ΔSB (deletion of SOCS box which is required for interaction with ElonginB/C and Cullin5 complex) mutants could decrease levels of endogenous NDR1 protein (Fig. 2H), suggesting that the SOCS-box domain is required for SOCS2 to regulate NDR1 abundance, likely mediated through the Cullin5 E3 ligase. Consistently, depletion of Cullin5 increased NDR1 protein levels (Fig. 2I). Over-expressed MycNDR1 did not have any detectable effects on the total protein levels of exogenous FLAGSOCS2 in MEFs (Fig. 2H). We also observed that the destabilizing effect of FLAGSOCS2 on MycNDR1 is further enhanced after treatment with TNFα (Fig. 2J). It is known that the interaction of SOCS2 with its target is mediated through phosphorylated tyrosine (Y) residue(s) on the substrate. Substitution of several of the Y residues on NDR1 with high probability of phosphorylation (source: PhosphoSitePlus database), could not abolish the ability of SOCS2 to degrade NDR1 (Figure S1), suggesting requirement of either multiple phospho-Y sites or Y residues other than the mutated ones. Collectively, these data demonstrate that NDR1 protein is regulated by SOCS2.
SOCS2 interacts with NDR1 leading to its polyubiquitination
Consistent with a role of SOCS2 in regulating NDR1 stability, over-expressed MycNDR1 was detected in exogenously expressed FLAGSOCS2ΔSB pull-down complexes and vice versa in HEK293T cells (Fig. 3A,B). We used a SOCS-box deleted form of SOCS2 for the pull-down assays to prevent SOCS2-induced degradation of NDR1 and to avoid Cullin5-interacting proteins in the immunoprecipitation. This interaction was confirmed in MEFs under endogenous conditions (Fig. 3C). We previously observed that FLAGSOCS2 over-expression could decrease levels of endogenous NDR1. This effect of SOCS2 on NDR1 is reversed by MG132 (26 S proteasome inhibitor) treatment (Fig. 3D), indicating that SOCS2 triggered reduction in NDR1 requires activity of the 26 S proteasome. Indeed, we observed a quantitative increase of high molecular weight polyubiquitinated forms of MycNDR1 upon FLAGSOCS2WT over-expression (Fig. 3E) but not FLAGSOCS2ΔSB over-expression (Fig. 3F) and these polyubiquitination was through K48-linkage (Fig. 3G). On the basis of above data, we propose that SOCS2 destabilizes NDR1 by promoting ubiquitination and its subsequent degradation by the 26 S proteasome.
SOCS2 deficiency stimulates NF-κB activation in response to TNFα
Because NDR1 potentiates NF-κB signaling in the presence of TNFα ligand18, we wished to evaluate the effect of SOCS2 on this aspect of NDR1 function due to its potential implications for clarifying the mechanisms behind SOCS2 anti-inflammatory actions, as mentioned above. However, before delving on to the functional implications of SOCS2 perturbations on NDR1-potentiated NF-κB signaling, we first asked what is the role of SOCS2 in TNFα-induced NF-κB activation in MEFs under our experimental conditions. IB analysis of cytoplasmic and nuclear extracts showed that MEFs depleted of SOCS2 (SOCS2KD) had significantly higher nuclear p65 levels, as compared to wild-type (SOCS2WT) cells, after stimulation with TNFα (Fig. 4A). We obtained similar results using high-content quantitative imaging (HCQI) (Figure S2A, B and Fig. 4B,C) which allowed detection of nuclear p65 quantitatively in situ19,20. Consistently, SOCS2KD cells were hyper-responsive to TNFα ligand with respect to NF-κB activity as determined by luciferase reporter assay (Fig. 4D) and changes in mRNA levels of the NF-κB target gene IL-6 (Figure S2C and Fig. 4E). We also observed that SOCS2 depletion resulted in changes in proteins secreted by TNFα-stimulated MEFs that promoted NF-κB transactivation in wild-type cells (i.e., in a paracrine manner) (Fig. 4F–I). We contextualize our in vitro data in an in vivo setting by using the murine DSS (dextran sodium sulphate) model of ulcerative colitis (UC)21 where TNFα is a major driving factor22. DSS-administered induction of UC has not been previously reported in SOCS2 knock-out (SOCS2−/−) mice. We found that in comparison to wild type mice, colonic tissue from SOCS2−/− mice showed exacerbated inflammation upon DSS treatment (Fig. 4J,K). Consistently, we observed much stronger nuclear staining for p65 in SOCS2−/−, as compared to SOCS2WT, mice after DSS administration (Fig. 4L) which was reflected in higher transcript levels of known NF-κB target genes, iNOS and IL-1β (Fig. 4M). As a whole, our observations indicate that SOCS2 depletion facilitates NF-κB signaling.
NDR1-mediated TNFα-induced NF-κB transactivation is inhibited by SOCS2
Having observed that SOCS2 depletion promotes several aspects of TNFα-induced NF-κB signaling in MEFs, we next asked how does this correlate to NDR1. In MEFs, transient over-expression of NDR1 amplifies TNFα-induced NF-κB signaling (Figure S3A–C). Consistently, depletion of NDR1 causes reduction of NF-κB dependent luciferase activity in both presence and absence of external TNFα stimulation, although the effect is more pronounced in presence of TNFα (Fig. 5A,B). Using HCQI we show that over-expression of NDR1 and down-regulation of SOCS2 had a combined additive effect on TNFα-induced nuclear translocation of p65 (Fig. 5C). Further, depletion of SOCS2 increased luciferase readout over TNFα stimulation alone, while knock-down of either NDR1 or double knock-down of both NDR1 and SOCS2 reduced NF-κB luciferase reporter activity below that of TNFα treatment (Fig. 5D) suggesting NDR1 to be downstream of SOCS2. Conversely, SOCS2 over-expression should diminish the strengthened transactivation potential of NF-κB in response to TNFα. To test this, we measured mRNA levels of well-known NF-κB target genes (MCP-1, NFKB1A and Arginase-1) using quantitative real-time PCR (qPCR) analysis upon NDR1 and SOCS2 overexpression either alone or in combination in MEFs (Fig. 5E). We observed that overexpression of SOCS2 alone stimulated the transcription of these genes. This is not unexpected given these genes may not be exclusively regulated by NF-κB under resting conditions and apparently depend on unidentified factors that are influenced by SOCS2. Nevertheless, NDR1 had an augmenting effect on the transcription of all the genes tested, and importantly, in all instances SOCS2 truncated this effect (Fig. 5E). We also provide a correlative support to our in vitro observations by showing that inflamed SOCS2−/− colonic tissues isolated from DSS-treated mice had elevated total levels of NDR1 protein as compared to similarly treated wild-type mice (Fig. 5F,G).
As a whole, our observations potentially point towards an explanation for the effects of SOCS2 on NF-κB activity and the hyper-inflammatory phenotype of SOCS2 deficient animals.
NDR1 amplifies the aggressive behaviour of PC3 cells
We previously observed that SOCS2 acts as a tumour suppressor in advanced castration-resistant prostate cancer. Bone metastases clinical samples of human patients exhibit reduced levels of SOCS2 in comparison with localized or hormone naive untreated adenocarcinomas23. A majority of these advanced tumors are known to have an elevated dependency on NF-κB signaling for their survival24. Since SOCS2 deficiency could lead to an elevated NDR1 levels, we wanted to see how an “over-expressing” NDR1 protein itself would impinge on the tumorigenic properties of cancer cells. As per our knowledge this has not been tested before. For this we selected PC3 prostate cancer cells, partly because of their “addiction” to NF-κB signaling25,26. To determine whether NDR1 over-expression alters the anchorage-independent growth of PC3 cells we performed soft-agar colony-formation assay and observed a marked difference in the number of colony-forming units. NDR1-overexpression in PC3 cells (PC3-NDR1) potentiated sphere-forming capacity by ~2.9-fold as compared to cells transfected with empty vector (PC3-EV) (Fig. 6A). However, PC3-NDR1 cells did not appear to have a significantly altered cell cycle profile in comparison to PC3-EV cells as measured using FACS analysis (Fig. 6B). PC3-NDR1 cells also had relatively higher invasive potential through Matrigel chamber (Fig. 6C). We next performed 2-dimensional wound-healing assay to test the migratory behaviour of these cells and found that PC3-NDR1 cells repopulated the cell-free clearing produced by the scratch faster than PC3-EV cells, indicating an increased migration rate. Importantly, inclusion of the NF-κB inhibitor parthenolide abrogated wound-healing capacity of both PC3-EV and PC3-NDR1 cells (Fig. 6D) highlighting the crucial role played by NF-κB in these cells. Taken together, these data demonstrate that NDR1 might act as a driver of oncogenic growth in NF-κB addicted tumors, although further research is needed to fully justify this claim.
Discussion
As mentioned above, the intracellular mechanisms by which anti-inflammatory actions are exerted by SOCS2 are poorly understood. This problem is related with our scarce knowledge of its cellular targets. To shed light on this aspect, we performed an unbiased nanoLC-MS/MS based quantification of cellular proteins in MEFs after transient knock-down of SOCS2 and enlisted 136 upregulated proteins. Of note, based on this experimental design we cannot rule out the contribution of secondary effects to changes in protein concentration, and the numbers of direct targets of SOCS2 are likely to be lower. Thus, additional research is needed to establish whether and how proteins identified in this analysis as putative SOCS2 targets are indeed ubiquitinated by SOCS2 and how they contribute to its cellular functions, including inflammation. Nonetheless, as it stands, this is the first report of a global quantitative proteomics effort specifically directed towards identification of SOCS2 regulated proteins.
Our proteomic data revealed NDR1 as a potential target for SOCS2 ubiquitin ligase activity. NDR1 (or STK38) is a serine-threonine kinase. It belongs to the LATS/NDR family and controls many critical processes including centrosome duplication27, apoptosis and proliferation28, chromosome alignment29. It regulates signaling pathways such as MEKK1/230, TGFβ31, Hippo32 and TLR933. Recently, NDR1 was shown to potentiate NF-κB signaling in the presence of TNFα ligand in HEK293T and HeLa cells18. Evidences indicate NDR1 protein is highly regulated through phosphorylation32 and the ubiquitin proteasome system31. Several kinases, including MST134 and GSK3β35 are known to regulated NDR1 activity under various contexts. However, no physiological E3 ligase had yet been reported for NDR1.
Using immunoprecipitation, we show that SOCS2 and NDR1 exist in the same complex. NDR1 was found to be a substrate of wild-type SOCS2 but not a SOCS-box truncated form i.e., SOCS2-ΔSB. SOCS2 acts as the substrate recognition module of Cullin5/Rbx2 E3 ligase “holoenzyme” and depends on its C-terminus SOCS box to interact with the complex, suggesting the involvement of Cullin5 E3 ligase. Consistently, knock-down of Cullin5 using RNAi stabilized NDR1 protein. Overexpression of SOCS2 increases polyubiquitination of NDR1 subsequently targeting it to 26S proteasomes as indicated by an increased ubiquitin-NDR1 conjugates in presence of MG132. We also provide data to support that SOCS2 ubiquitination of NDR1 is mediated mainly by K48-Ub-specific linkages that are mostly associated with proteolysis. Conversely, our data showing stabilization of NDR1 upon SOCS2 depletion indicates a constitutive ligase-substrate relation between them.
Considering some of the latest evidences, it appears that SOCS2 probably orchestrates multiple regulatory nodes in the inflammatory pathway8,36,37,38. We observed that over-expression of NDR1 alone had a two-fold enhancing effect on NF-κB transactivation, as judged by qPCR of well-known NF-κB target genes. Not surprisingly, the overall impact was much stronger when the cells were induced with TNFα but the fold change was still ~2.0 fold. Therefore, our report agrees with Shi et al., that NDR1 potentiates TNFα induced NF-κB signaling, however, the mechanism behind this effect is yet to be uncovered. Here we report SOCS2 induced destabilization of NDR1. SOCS2 can constitutively degrade NDR1 without an activating stimulus (other than provided by standard cell culture conditions), although interestingly, a TNFα stimulus seem to make NDR1 a better target of SOCS2. Based on our proteomics observations, we believe that NDR1 protein is relatively more abundant than SOCS2 because we repeatedly detected NDR1 by mass spectrometry analysis but not SOCS2. This might mean that manipulating SOCS2 levels may serve a switch for controlling TNFα-NF-κB signaling mediated through NDR1.
We offered evidence that SOCS2 regulation of NDR1 may be relevant for inflammation and carcinogenesis. Our observations showing elevated tumorigenic properties of PC3 cells in response to NDR1 over-expression raises interesting questions and begs further research into the carcinogenic role of NDR1. Given the role of NF-κB signaling in multiple human malignancies, our study raises the potential for SOCS2-NDR1-NF-κB axis as a target for drug discovery in inflammation and cancer biology.
Overall, the data presented in this study (1) provides evidence for an inhibitory role of SOCS2 in TNFα induced NF-κB activation, (2) identifies NDR1 as a novel substrate of SOCS2, and (3) demonstrates that SOCS2 and TNFα induced NF-κB signaling are linked through NDR1. Through this study, we provide a mechanistic explanation for the well-acknowledged hyper-inflammatory phenotype of SOCS2-deficient animals (Fig. 7).
Materials and Methods
Cell Culture, transfection and drug treatments
Cells were cultured using standard protocols. Transfections of DNA constructs and siRNAs were performed using Neon® Transfection System (Thermo Fisher Scientific) according to the manufacturer’s instructions. The following drugs/inhibitors were used: MG132, cycloheximide (Sigma-Aldrich), mouse and human recombinant TNFα (Invitrogen). Concentrations used and incubation times are given in Figure legends.
Expression plasmids and siRNA
Human SOCS2 gene (NM_003877) was PCR amplified from total HEK293T cDNA. Full-length SOCS2 and SOCS2ΔSB deletion mutant (amino acids 1–145) were cloned into pcDNA 4/TO vector with an N-terminal FLAG epitope to generate FLAGSOCS2WT and FLAGSOCS2ΔSB. pcDNA4/TO-HA-Strep-ubiquitin WT, K48-only and K48R were a kind gift from Niels Mailand (University of Copenhagen). Myc-tagged NDR1 was obtained from Addgene (Plasmid #37023, a kind gift from Yutaka Hata). Point mutations of Myc-NDR1 were created using the site-directed mutagenesis kit (Agilent Technologies) as per manufacturer’s instructions. All plasmids were verified by sequencing. Sequences of primers used can be provided upon request. All siRNAs were purchased from Qiagen and used at a final concentration of 80 nM. Sequences are given in Table S2.
Preparation of conditioned medium
Cells were starved in serum-free media for 16 hours before being pulsed with TNFα (10 ng/ml) for 1 hour after which residual TNFα was washed twice using PBS. Serum-free media was again replenished and cells were inubated for another 4 hours. CM were collected, clarified by centrifugation and passed through sterile 0.22 μm sterile filter. CM were used freshly.
Co-immunoprecipitation (co-IP) and immunoblot (IB) analyses
For co-IP experiments, cells were lysed on ice using IP buffer (50 mM HEPES, pH 7.2, 250 mM NaCl, 10% glycerol, 1% Nonidet P-40, 1.0 mM EDTA, 10 mM phenylmethanesulfonylfluoride (PMSF), 50 mM sodium fluoride, 0.2 mM sodium orthovanadate (Na3VO4), 25 mM β-glycerophosphate and protease inhibitor cocktail from Roche). After pre-clearing with Protein A Sepharose beads (Amersham Biosciences), 2 mg of total protein was subjected to immunoprecipitation as described previously39. For western blotting, cells were lysed on ice using RIPA buffer (50mM Tris pH 7.4, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X 100, 10 mM phenylmethanesulfonylfluoride (PMSF), 50 mM sodium fluoride, 0.2 mM sodium orthovanadate (Na3VO4), 25 mM β-glycerophosphate and protease inhibitor cocktail from Roche). The following antibodies were used: Santacruz Biotechnology - GAPDH, Myc (9E10), NDR1(STK38), Ubiquitin; Sigma - β-actin, HA, FLAG(M2); Abcam – SOCS2; Abnova – NDR1; Cell Signaling Technology – SOCS2, p65, FLAG. Pixel densitometric measurements of immunoblots was done using the ImageJ software (https://fiji.sc/).
Orbitrap Q-Exactive MS/MS and proteomics data analysis
Lysates were prepared as described previously40. From each sample, 100 μg of proteins were first digested with Lys-C (4 hours at 37 °C) followed by dilution of guanidine hydrochloride to <2 M with 50 mM ammonium bicarbonate prior to the addition sequencing grade Trypsin (overnight at 37 °C). Enzyme activity was quenched by acidification of the samples with trifluoroacetic acid (TFA) and the peptide mixture was desalted and concentrated on a C18 Stagetip before elution with 50% acetonitrile, 0.1% TFA. The eluate was concentrated in a SpeedVac at 60 °C and acidified with 5% ACN, 1% TFA before being analyzed using an EASY-nLC system (Proxeon) connected to a Q Exactive mass spectrometer (Thermo Fisher Scientific) through a nano-electrospray ion source. Peptides were separated in a 15-cm analytical column (75 μm inner diameter) in-house packed with 1.9 μm diameter reversed-phase C18 beads (ReproSil-Pur AQ, Dr. Maisch) with an increasing gradient from 5 to 30% buffer B (80% acetonitrile, 0.1% formic acid) in 120 minutes at a flow rate of 250 nl/min followed by an increase to 40% B in 15 minutes where it was briefly held prior to 80% B for 5 minutes followed by column re-equilibration at 5% B. The Q-Exactive was operated in data-dependent acquisition mode using the “sensitive scanning method”41. Raw MS files from the Q-Exactive were analyzed by MaxQuant 1.4.1.1 with the Andromeda search engine42. Tandem mass spectrometry spectra were searched against the decoy International Protein Index-Mus musculus database version 3.62 containing both forward and reverse protein sequences. The search included variable modifications of methionine oxidation and N-terminal acetylation, and fixed modification of cysteine carbamidomethylation. Peptides of minimum seven amino acids and maximum of two missed cleavages were allowed for the analysis. False discovery rate of 1% was used for the identification of peptides and proteins. Bioinformatics analysis of the data were mainly performed using the Perseus computational platform43 and text mining in PubMed using the search string: ((NF-κB[Title]) AND gene1[Title]) OR gene2[Title] etc. for all identified proteins with a P-value < 0.05 and Fold change >1.5.
Luciferase assays
Luciferase activity of NF-κB reporter was determined luminometrically using the Dual-Glo luciferase assay system (Promega). MEFs (106) were transiently transfected with pGL4.74-hRluc/TK (10 ng) and pGL4.10.NF-κB reporter (100 ng) vectors along with the indicated constructs. Luciferase activity of cell extracts in passive lysis buffer was determined luminometrically using the Varioskan multiplate reader (Thermo Fisher Scientific).
Microscopy
Protocol has been described before39. For High-Content Quantitative Imaging (HCQI), photographs were captured on Olympus IX-81 motorized fluorescence microscope equipped with an Olympus UPLSAPO 20x/0.75 NA objective. Automated and unbiased image analysis was carried out with the ScanR acquisition software. For confocal fluorescence microscopy, images were captured on a Zeiss LSM 700 imaging system.
Quantitative real-time PCR (qPCR)
Total RNA was extracted using the RNeasy kit (Qiagen). For each sample, 1 μg of RNA was converted to cDNA using iScript cDNA synthesis kit (Biorad), diluted 1:5 with water and subsequently used for qPCR analysis using Brilliant III ultra-fast SYBR® green (Agilent Technologies) on a 7500 Fast Real-Time PCR system (Applied Biosystems). In all experiments, 18S rRNA served as the internal control (normalization) and calibrator controls were chosen appropriately. Sequences of the primers used are given in Table S3.
Immunohistochemistry
Tissue sections were deparaffinized in xylene and rehydrated through graded ethanol. For antigen retrieval slides were steamed for 30 minutes in EnVision FLEX Target Retrieval Solution (pH 6.1) (Dako). Antibody incubations were done overnight at 4 °C in Shandon coverplates (Thermo Fisher Scientific). For detection, HiDef HRP polymer system (Sigma-Aldrich) was used followed by incubation with DAB + chromogen (DAKO) according to manufacturer’s instructions. Slides were counterstained with Mayers hematoxylin for 1 minute. All immunohistochemical procedures were undertaken in one batch. The antibody for p65 was from Cell Signaling Technology.
Laboratory Animals and Experimental Colitis
Mice were housed under standard conditions [12:12-hour light-dark cycles, 22 ± 2 °C and about 60% humidity] with ad libitum feeding. Male SOCS2 knockout (SOCS2−/−) and SOCS2-wild type (SOCS2+/+) littermate mice between 12–16 weeks’ old were used and they were allowed to acclimate to these conditions for a week before the start of the experiment. Colonic inflammation was induced by oral administration of 3% (w/v) Dextran Sodium Sulfate (DSS; T&D consulting, Uppsala, Sweden) dissolved in drinking water for 5 days and then switched to normal drinking water until day 20. Mice were sacrificed after euthanasia by total bleeding and cervical dislocation after anesthesia by isoflurane. Entire colons of DSS treated and untreated mice were dissected and contents flushed with ice-cold saline. The distal third of the colon was dissected into equal pieces for histological analysis and RNA & protein extractions. Following H + E staining, specimens were evaluated for histological colitis scoring by two independent pathologist using light microscopy. The scoring of histological changes in the colon was done according to Cooper et al.44, which include the assessment of Crypt loss, infiltration of neutrophil, lymphocytes and goblet cell depletion45,46. Histological findings were given a score based on the severity of the colitis (Table S4). Animal handling and all experimental protocols were performed in accordance with the relevant guidelines and regulations approved by the “Animal Ethics Committee” of Sultan Qaboos University, Oman.
Soft-agar colony formation assay
For soft-agar assays, 300 cells were suspended in RPMI containing 0.35% agar and layered on top of 1 ml of RPMI solidified with 1.0% agar in each 35-mm dish. After growing at 37 °C for 14 days, colonies were visualized and counted in three different microscopic fields.
Wound healing assay
The migratory behavior of PC3 cells were evaluated using the scratch (wound healing) assay. Briefly, equal number of cells were seeded on 6-well plates and allowed to reach confluency. Several scratches were made using a 200 μl pipette tip spanning the well. Migration of cells was observed at premarked positions below the wells using an Olympus IX81 inverted microscope at 40X magnification.
Matrigel invasion assay
Matrigel (60 μl at 1:4 dilutions in RPMI medium) was coated on the top of Transwell filters (6.5-mm diameter, 8.0-μm pore size, Costar, Corning, NY) for 4 h at 37 °C. Chemoattractant (10 ng/ml TNFα) was added to bottom chambers of transwells and cells (50,000) were plated on Matrigel in RPMI and allowed to migrate overnight at 37 °C through Matrigel. Migrated cells were fixed in 4% paraformaldehyde in PBS for 15 minutes and permeabilized with 0.2% Triton -X100 in PBS for 10 minutes. Cells migrated to the lower chamber were stained with 0.5 μg/ml DAPI in PBS. Fluorescence pictures were acquired using an Olympus IX81 inverted microscope at 40X magnification from three random fields and nuclei were counted using ImageJ.
Statistical analysis
All statistical calculations were done using the GraphPad QuickCalcs software. Student’s t-test (unpaired) was used. A P value of < 0.05 was taken as significant and < 0.005 was considered extremely significant. For proteomics experiments, P values were calculated using the inbuilt statistical functions of Perseus platform.
Additional Information
How to cite this article: Paul, I. et al. The ubiquitin ligase Cullin5SOCS2 regulates NDR1/STK38 stability and NF-κB transactivation. Sci. Rep. 7, 42800; doi: 10.1038/srep42800 (2017).
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Material
Acknowledgments
This work is supported by grants to AFM from the Novo Nordisk Foundation, The Danish Cancer Society and the Danish Research Council and grants to FZ from “His Majesty Trust Fund SR/MED/BIOC/13/01”. We would like to thank Niels Mailand at the NNF CPR for providing ubiquitin (K48 and K48R) constructs.
Footnotes
The authors declare no competing financial interests.
Author Contributions I.P., T.S.B. and D.I.G. performed M.S. sample preparation and analysis at the laboratory of J.V.O. where he provided infrastructure, reagents and expert advice. A.A.A., A.A., I.A.H. performed mouse experiments at the laboratory of F.Z. where he provided infrastructure, reagents and advice. G.N. provided valuable advice in preparation of the manuscript. I.P. conceived the study, designed and performed experiments, analyzed data and wrote the manuscript. A.F.M. designed experiments, analyzed data, co-wrote manuscript with IP and provided infrastructure and supervision.
References
- Metcalf D. et al. Gigantism in mice lacking suppressor of cytokine signalling-2. Nature 405, 1069–1073 (2000). [DOI] [PubMed] [Google Scholar]
- Vesterlund M. et al. The SOCS2 ubiquitin ligase complex regulates growth hormone receptor levels. PloS One 6, e25358 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
- Letellier E. & Haan S. SOCS2: physiological and pathological functions. Front. Biosci. Elite Ed. 8, 189–204 (2016). [DOI] [PubMed] [Google Scholar]
- Rico-Bautista E., Flores-Morales A. & Fernández-Pérez L. Suppressor of cytokine signaling (SOCS) 2, a protein with multiple functions. Cytokine Growth Factor Rev. 17, 431–439 (2006). [DOI] [PubMed] [Google Scholar]
- Hoesel B. & Schmid J. A. The complexity of NF-κB signaling in inflammation and cancer. Mol. Cancer 12, 86 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
- Baetz A., Frey M., Heeg K. & Dalpke A. H. Suppressor of Cytokine Signaling (SOCS) Proteins Indirectly Regulate Toll-like Receptor Signaling in Innate Immune Cells. J. Biol. Chem. 279, 54708–54715 (2004). [DOI] [PubMed] [Google Scholar]
- Park S.-H., Kim K.-E., Hwang H.-Y. & Kim T. Y. Regulatory Effect of SOCS on NF-κB Activity in Murine Monocytes/Macrophages. DNA Cell Biol. 22, 131–139 (2003). [DOI] [PubMed] [Google Scholar]
- Marsland B. J. Regulating inflammation with microbial metabolites. Nat. Med. 22, 581–583 (2016). [DOI] [PubMed] [Google Scholar]
- Zadjali F. et al. SOCS2 deletion protects against hepatic steatosis but worsens insulin resistance in high-fat-diet-fed mice. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 26, 3282–3291 (2012). [DOI] [PubMed] [Google Scholar]
- Favre H., Benhamou A., Finidori J., Kelly P. A. & Edery M. Dual effects of suppressor of cytokine signaling (SOCS-2) on growth hormone signal transduction. FEBS Lett. 453, 63–66 (1999). [DOI] [PubMed] [Google Scholar]
- Greenhalgh C. J. et al. Biological evidence that SOCS-2 can act either as an enhancer or suppressor of growth hormone signaling. J. Biol. Chem. 277, 40181–40184 (2002). [DOI] [PubMed] [Google Scholar]
- McIntosh C. A., Saiz F. J. S. & Minden M. D. SOCS2 Expression in AML: A Context Dependent Effect? Blood 110, 4152–4152 (2007). [Google Scholar]
- Tannahill G. M. et al. SOCS2 Can Enhance Interleukin-2 (IL-2) and IL-3 Signaling by Accelerating SOCS3 Degradation. Mol. Cell. Biol. 25, 9115–9126 (2005). [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lee S. H. et al. Suppressor of cytokine signaling 2 regulates IL-15-primed human NK cell function via control of phosphorylated Pyk2. J. Immunol. Baltim. Md 1950 185, 917–928 (2010). [DOI] [PubMed] [Google Scholar]
- Hansson J. et al. Highly coordinated proteome dynamics during reprogramming of somatic cells to pluripotency. Cell Rep. 2, 1579–1592 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
- Guo C. & Stark G. R. FER tyrosine kinase (FER) overexpression mediates resistance to quinacrine through EGF-dependent activation of NF-κB. Proc. Natl. Acad. Sci. 108, 7968–7973 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
- Dai T. et al. Golgi phosphoprotein 3 (GOLPH3) promotes hepatocellular carcinoma cell aggressiveness by activating the NF-κB pathway. J. Pathol. 235, 490–501 (2015). [DOI] [PubMed] [Google Scholar]
- Shi D.-D. et al. NDR1/STK38 potentiates NF-κB activation by its kinase activity. Cell Biochem. Funct. 30, 664–670 (2012). [DOI] [PubMed] [Google Scholar]
- Deptala A., Bedner E., Gorczyca W. & Darzynkiewicz Z. Activation of nuclear factor kappa B (NF-kappaB) assayed by laser scanning cytometry (LSC). Cytometry 33, 376–382 (1998). [DOI] [PMC free article] [PubMed] [Google Scholar]
- Noursadeghi M. et al. Quantitative imaging assay for NF-κB nuclear translocation in primary human macrophages. J. Immunol. Methods 329, 194–200 (2008). [DOI] [PMC free article] [PubMed] [Google Scholar]
- Perše M. & Cerar A. Dextran Sodium Sulphate Colitis Mouse Model: Traps and Tricks. BioMed Res. Int. 2012, e718617 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
- Danese S., Colombel J.-F., Peyrin-Biroulet L., Rutgeerts P. & Reinisch W. Review article: the role of anti-TNF in the management of ulcerative colitis – past, present and future. Aliment. Pharmacol. Ther. 37, 855–866 (2013). [DOI] [PubMed] [Google Scholar]
- Enomoto A. et al. Negative regulation of MEKK1/2 signaling by Serine-Threonine kinase 38 (STK38). Oncogene 27, 1930–1938 (2007). [DOI] [PubMed] [Google Scholar]
- Iglesias-Gato D. et al. SOCS2 mediates the cross talk between androgen and growth hormone signaling in prostate cancer. Carcinogenesis 35, 24–33 (2014). [DOI] [PubMed] [Google Scholar]
- Ben-Neriah Y. & Karin M. Inflammation meets cancer, with NF-κB as the matchmaker. Nat. Immunol. 12, 715–723 (2011). [DOI] [PubMed] [Google Scholar]
- Li Y. & Sarkar F. H. Inhibition of nuclear factor kappaB activation in PC3 cells by genistein is mediated via Akt signaling pathway. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 8, 2369–2377 (2002). [PubMed] [Google Scholar]
- Jin R. et al. Activation of NF-kappa B Signaling Promotes Growth of Prostate Cancer Cells in Bone. PLoS ONE 8, e60983 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hergovich A., Lamla S., Nigg E. A. & Hemmings B. A. Centrosome-associated NDR kinase regulates centrosome duplication. Mol. Cell 25, 625–634 (2007). [DOI] [PubMed] [Google Scholar]
- Joffre C., Codogno P., Fanto M., Hergovich A. & Camonis J. STK38 at the crossroad between autophagy and apoptosis. Autophagy 0, 00–00 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
- Chiba S., Ikeda M., Katsunuma K., Ohashi K. & Mizuno K. MST2- and Furry-mediated activation of NDR1 kinase is critical for precise alignment of mitotic chromosomes. Curr. Biol. CB 19, 675–681 (2009). [DOI] [PubMed] [Google Scholar]
- Pot I. et al. Identification of a Novel Link between the Protein Kinase NDR1 and TGFβ Signaling in Epithelial Cells. PLoS One 8, e67178 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hergovich A. Regulation and functions of mammalian LATS/NDR kinases: looking beyond canonical Hippo signalling. Cell Biosci. 3, 1–12 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wen M. et al. Stk38 protein kinase preferentially inhibits TLR9-activated inflammatory responses by promoting MEKK2 ubiquitination in macrophages. Nat. Commun. 6, 7167 (2015). [DOI] [PubMed] [Google Scholar]
- Hergovich A. et al. The MST1 and hMOB1 tumor suppressors control human centrosome duplication by regulating NDR kinase phosphorylation. Curr. Biol. CB 19, 1692–1702 (2009). [DOI] [PubMed] [Google Scholar]
- Enomoto A., Kido N., Ito M., Takamatsu N. & Miyagawa K. Serine-threonine kinase 38 is regulated by glycogen synthase kinase-3 and modulates oxidative stress-induced cell death. Free Radic. Biol. Med. 52, 507–515 (2012). [DOI] [PubMed] [Google Scholar]
- Esper L. et al. Role of SOCS2 in Modulating Heart Damage and Function in a Murine Model of Acute Chagas Disease. Am. J. Pathol. 181, 130–140 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
- Knosp C. A. et al. Regulation of Foxp3+ inducible regulatory T cell stability by SOCS2. J. Immunol. Baltim. Md 1950 190, 3235–3245 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
- McCormick S. M. & Heller N. M. Regulation of macrophage, dendritic cell, and microglial phenotype and function by the SOCS proteins. Inflammation 549, doi: 10.3389/fimmu.2015.00549 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- Paul I., Ahmed S. F., Bhowmik A., Deb S. & Ghosh M. K. The ubiquitin ligase CHIP regulates c-Myc stability and transcriptional activity. Oncogene 32, 1284–1295 (2013). [DOI] [PubMed] [Google Scholar]
- Jersie-Christensen R. R., Sultan A. & Olsen J. V. Simple and Reproducible Sample Preparation for Single-Shot Phosphoproteomics with High Sensitivity. Methods Mol. Biol. Clifton NJ 1355, 251–260 (2016). [DOI] [PubMed] [Google Scholar]
- Kelstrup C. D. et al. Rapid and deep proteomes by faster sequencing on a benchtop quadrupole ultra-high-field Orbitrap mass spectrometer. J. Proteome Res. 13, 6187–6195 (2014). [DOI] [PubMed] [Google Scholar]
- Cox J. & Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367–1372 (2008). [DOI] [PubMed] [Google Scholar]
- Tyanova S. et al. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat. Methods 13, 731–740 (2016). [DOI] [PubMed] [Google Scholar]
- Cooper H. S., Murthy S. N., Shah R. S. & Sedergran D. J. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab. Investig. J. Tech. Methods Pathol. 69, 238–249 (1993). [PubMed] [Google Scholar]
- Ali B. H. et al. Comparative efficacy of three brands of gum acacia on adenine-induced chronic renal failure in rats. Physiol. Res. Acad. Sci. Bohemoslov. 62, 47–56 (2013). [DOI] [PubMed] [Google Scholar]
- Håkansson Å. et al. Immunological alteration and changes of gut microbiota after dextran sulfate sodium (DSS) administration in mice. Clin. Exp. Med. 15, 107–120 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- Tuominen V. J., Ruotoistenmäki S., Viitanen A., Jumppanen M. & Isola J. ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67. Breast Cancer Res. 12, R56 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.